Esperion Therapeutics reports positive top-line results on ETC-1002

|About: Esperion Therapeutics (ESPR)|By:, SA News Editor

Esperion Therapeutics (ESPR) says Phase 2a study results show ETC-1002 achieved incremental bad cholesterol lowering of 22% at eight weeks versus 0% for placebo when added to atorvastatin.

The results put the company in a position to "build on [the] positive results with a ... Phase 2b study to establish further the potential of ETC-1002," CEO Tim Mayleben says. (PR)